Immunai is a biotechnology company that develops single-cell immune profiling and computational platforms to map the human immune system. The company combines high-throughput single-cell assays, multi-omic data integration, and machine-learning analytics to identify immune cell states, biomarkers, and therapeutic targets for drug discovery and translational research partnerships.
Estimated Valuation
Leadership & Board
Current Number of Employees173
Current LinkedIn Followers28,358
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$215M
Total Amount Raised$215M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$215M
Latest Funding Amount$215M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Immunai had 173 employees as of September 7, 2026. The number of employees increased by 0 (0.00%) week-over-week.
173Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Immunai had 28,358 followers as of September 7, 2026. The number of followers increased by 107 (0.38%) week-over-week.
28,358Latest Followers Count
107(0.38%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.
Funding Round
Nov 27, 2021
Series B
$215.00M
―
Investors
Series B
Similar Companies
A snapshot of private companies similar to Immunai, helping you discover and navigate related company profiles.
